Showing results (161-170 of 222) with videos related to
Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid MalignanciesDejan Juric, Johann S de Bono, Patricia M LoRusso, et al.The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.NPJ Digital Medicine|June 30, 2026
Structured reasoning failures compromise LLM interpretation of clinical oncology notesMatthew W Kenaston, Umair Ayub, Mihir Parmar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomasMonica M Mita, Matthew A Spear, Lorrin K Yee, et al.Cells|April 30, 2021
Lysine 53 Acetylation of Cytochrome c in Prostate Cancer: Warburg Metabolism and Evasion of ApoptosisViktoriia Bazylianska, Hasini A Kalpage, Junmei Wan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell CarcinomasJohn A Thompson, Robert J Motzer, Ana M Molina, et al.Cancers|May 25, 2024
Characterization of FOLH1 Expression in Renal Cell CarcinomaEric Ovruchesky, Elizabeth Pan, Melis Guer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaDaniel P Petrylak, Bernhard J Eigl, Saby George, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.Pageof 23